The Food and Drug Administration has recently approved sorafenib and sunitinib, two oral multitargeted tyrosine kinase inhibitors, for the treatment of advanced renal cell carcinoma (RCC). Because of the central role of vascular endothelial growth factor (VEGF) in this disease and the activity of
No takes yet. Share an insight, caveat, or question.
Stein et al. (2007) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: